A Phase I/Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Chinese Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors With Expansion to Selected Indication(s)
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2019
At a glance
- Drugs Avelumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck KGaA
- 06 Sep 2018 Planned End Date changed from 3 Dec 2019 to 21 Oct 2019.
- 21 May 2018 Planned End Date changed from 17 May 2020 to 3 Dec 2019.
- 21 May 2018 Planned primary completion date changed from 2 Jun 2019 to 21 Oct 2019.